Form 8-K - Current report:
SEC Accession No. 0001549595-26-000034
Filing Date
2026-06-11
Accepted
2026-06-11 07:06:57
Documents
12
Period of Report
2026-06-11
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrix-20260611.htm   iXBRL 8-K 35141
2 EX-99.1 ex991_nurixpressrelease202.htm EX-99.1 25050
  Complete submission text file 0001549595-26-000034.txt   187762

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nrix-20260611.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nrix-20260611_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nrix-20260611_pre.xml EX-101.PRE 13046
16 EXTRACTED XBRL INSTANCE DOCUMENT nrix-20260611_htm.xml XML 3180
Mailing Address 1600 SIERRA POINT PKWY BRISBANE CA 94005
Business Address 1600 SIERRA POINT PKWY BRISBANE CA 94005 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 261081428
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)